Related Experiment Videos
Hypercalcemia and idiopathic hypoparathyroidism
M Schroth1, J Dötsch, H G Dörr
1Klinik mit Poliklinik für Kinder und Jugendliche, Friedrich-Alexander-Universität Erlangen-Nürnberg, Loschgestrasse 15, D-91054 Erlangen, Germany. michael_schroth@yahoo.de
Journal of Clinical Pharmacy and Therapeutics
|November 28, 2001
Summary
Patients with idiopathic primary hypoparathyroidism (prHP) require stopping calcium and calcitriol during immobilization. Failure to do so can lead to hypercalcemia and renal failure, necessitating vigilant laboratory monitoring.
Area of Science:
- Endocrinology
- Nephrology
- Rare Diseases
Background:
- Idiopathic primary hypoparathyroidism (prHP) is a rare endocrine disorder with limited clinical management experience.
- Patients with prHP often require calcium and calcitriol supplementation.
- Prolonged immobilization poses a risk for metabolic complications in prHP patients.
Observation:
- A case of a young male patient with prHP is presented.
- The patient underwent a 2-month period of prolonged immobilization.
- During immobilization, calcium and calcitriol supplementation was continued.
Findings:
- The patient developed severe hypercalcemia and acute renal failure.
- These complications were directly attributed to the unadjusted calcium and calcitriol substitution during immobilization.
- Discontinuation of supplementation and close monitoring were crucial for recovery.
Implications:
- This case highlights the critical need to halt calcium and calcitriol substitution in prHP patients during prolonged immobilization.
- Continuous laboratory monitoring for hypercalcemia and renal function is mandatory in immobilized prHP patients.
- Adherence to these management guidelines can prevent severe metabolic derangements and kidney injury.